ProfileGDS4814 / ILMN_1770787
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 70% 70% 72% 70% 67% 70% 66% 70% 69% 64% 70% 63% 69% 70% 68% 70% 71% 69% 69% 70% 68% 69% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)75.120870
GSM780708Untreated after 4 days (C2_1)74.935270
GSM780709Untreated after 4 days (C3_1)82.861972
GSM780719Untreated after 4 days (C1_2)74.380370
GSM780720Untreated after 4 days (C2_2)63.627367
GSM780721Untreated after 4 days (C3_2)74.196670
GSM780710Trastuzumab treated after 4 days (T1_1)61.892866
GSM780711Trastuzumab treated after 4 days (T2_1)72.868870
GSM780712Trastuzumab treated after 4 days (T3_1)70.434669
GSM780722Trastuzumab treated after 4 days (T1_2)58.828764
GSM780723Trastuzumab treated after 4 days (T2_2)71.929470
GSM780724Trastuzumab treated after 4 days (T3_2)57.983663
GSM780713Pertuzumab treated after 4 days (P1_1)70.851869
GSM780714Pertuzumab treated after 4 days (P2_1)72.370370
GSM780715Pertuzumab treated after 4 days (P3_1)66.768268
GSM780725Pertuzumab treated after 4 days (P1_2)74.801470
GSM780726Pertuzumab treated after 4 days (P2_2)75.51571
GSM780727Pertuzumab treated after 4 days (P3_2)71.069369
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)71.534369
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)72.406470
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)66.888568
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)69.555769
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)72.126470